# Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

> **NCT02217644** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 653048 H3PO4 solution
- **DRUG:** BI 653048 H3PO4 low dose capsule
- **DRUG:** BI 653048 H3PO4 high dose capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02217644
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02217644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02217644, "Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02217644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*